At Screen4PN, we offer cutting-edge in vitro models derived from patient-specific induced pluripotent stem cells (iPSCs). Our 2D and 3D cellular platforms enable accurate compound validation studies for peripheral neuropathies, with a strong focus on Charcot-Marie-Tooth (CMT) disease and related disorders.
Patient-derived induced pluripotent stem cells
We offer a diverse biobank of induced pluripotent stem cell (iPSC) lines, including healthy control lines, patient-specific lines and isogenic controls. Each line undergoes stringent quality control for genetic stability, pluripotency, and sterility. Our biobank covers a broad spectrum of CMT subtypes. Whether you’re studying axonal, demyelinating, or mixed forms of CMT, we provide the cellular tools to accelerate your discovery.
Advanced 2D & 3D disease models
Screen4PN develops and offers multiple in vitro models tailored to mimic distinct disease phenotypes relevant to peripheral neuropathies. Each model is carefully optimized to reflect different aspects of pathophysiology—including axonal degeneration and impaired myelination.
Our models have been published in journals and are developed with drug discovery and phenotypic screening in mind. Rather than a one-size-fits-all approach, we offer a complementary model suite, each shedding light on different mechanistic layers of the disease, together providing a powerful system for therapeutic development.
Compound validation with specialized readouts
We provide in-house evaluation of compound effects using a wide array of functional and molecular readouts. Our approach is highly flexible and collaborative. We tailor every project to your scientific questions and compound profile.